The ADDF offers funding to researchers in both nonprofit and for-profit organizations for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. Visit our Research Priorities for specific information about our interests.

Our funding is open to:
• Researchers, clinicians, and postdoctoral fellows
• Working in academia and biotechnology companies
• Based in the U.S. and worldwide

The ADDF currently accepts grant proposals through the following RFPs. For returning grantees, we accept proposals for follow-on funding and renewals.

ADDF FUNDING PORTAL

LOG IN OR
CREATE ACCOUNT

We provide applicants with a streamlined review process—the average time from letter of intent (LOI) decision to award decision is less than four months. For most RFPs, letters of intent are accepted and reviewed on a rolling basis during four cycles each year, corresponding to our four invited full proposal reviews.

Read our policies on application submissions and funding.

CORE REQUESTS FOR PROPOSALS


Deadline Cycles for Core RFPs:

Letter of Intent
February 17, 2017

Invited Full Proposal
March 10, 2017

Letter of Intent
May 19, 2017

Invited Full Proposal
June 9, 2017

Letter of Intent
July 31, 2017

Invited Full Proposal
September 8, 2017

Letter of Intent
November 17, 2017

Invited Full Proposal
December 8, 2017

 
 

Program to Accelerate Clinical Trials (PACT) RFP

Seeks to fund Phase 1 safety testing, Phase 2 biomarker-based, proof-of-concept pilot clinical trials, and IND-enabling studies.

 
 

Biomarkers Development RFP

Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.

 
 

Prevention Beyond the Pipeline RFP

Seeks to support comparative effectiveness research, clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

 
 

Preclinical Drug Discovery RFP

Seeks to fund promising preclinical drug discovery for Alzheimer's disease, related dementias, and cognitive aging.

 

 

OTHER REQUESTS FOR PROPOSALS


Accelerating Drug Discovery for Frontotemporal Degeneration RFP

Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration.

Deadlines

Passed

 

 

OTHER ADDF FUNDING OPPORTUNITIES


ADDF/NIH Funding

Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.

 
 

Conference Funding

Supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information, email grants@alzdiscovery.org with a brief summary of your conference

 


Stay Updated on Upcoming Deadlines and RFP Announcements

Sign up to receive news by email.

Print